Abstracts » Business

BioPulse faces US and Mexican malpractice probes

Article Abstract:

On February 2 2001, The U.S. Federal Trade Commission opened an investigation into BioPulse International's claim on its website that it can successully treat cancer patients with up to 95 percent effectiveness, using the company's unproven methods at its Tijuana clinic. On February 15, the Mexican government closed part of the clinic.

Administration of General Economic Programs, Advertising, New Electronic Marketing, Mexico, Admin. of general economic programs, Federal Trade Commission, Biopulse International Inc.

---

Company, academics argue over data

Article Abstract:

Immune Response Corp. filed suit against the University of California San Francisco, and Harvard University for publishing phase III drug trial information, which suggests that the company's HIV drug Remune is no more effective than a placebo in fighting HIV infection.

Marketing procedures, Company Planning/Goals, California, Massachusetts, General Medical and Surgical Hospitals, General medical & surgical hospitals, Antiinfective Preparations NEC, University Medical Centers, Anti-infective agents, University hospitals, Remune (Medication), Immune Response Corp., IMNR

---

Analysts: Isis-Lilly deal validates antisense

Article Abstract:

Eli Lilly and Isis Pharmaceuticals strike a deal to facilitate development of "antisense" technology, which interferes with production of disease-causing proteins in RNA. Eli Lilly would also receive rights to lung cancer drug, ISIS 3521, as part of the agreement.

Biological Product (except Diagnostic) Manufacturing, Strategic alliances, Drugs, Oligonucleotides, Eli Lilly and Co., Isis Pharmaceuticals Inc., LLY, Nucleotides, ISIP

Some parts © 2012 Advameg, Inc.